Anticoagulants: Difference between revisions
Neil.m.young (talk | contribs) |
Neil.m.young (talk | contribs) |
||
| Line 42: | Line 42: | ||
*[[Anticoagulant reversal for life-threatening bleeds]] | *[[Anticoagulant reversal for life-threatening bleeds]] | ||
*[[Antiplatelet medications]] | *[[Antiplatelet medications]] | ||
*[[Procedures in patients with coagulopathies]] | |||
==References== | ==References== | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 14:48, 3 April 2022
Contraindications to Anticoagulation[1]
- Absolute:
- Active bleeding
- Severe bleeding diathesis or platelet count <20K
- Neurosurgery, ocular surgery, or intracranial bleeding in the last 10 days
- Relative:
- Mild-to-moderate bleeding diathesis or thrombocytopenia
- Brain metastases
- Recent major trauma
- Major abdominal surgery within the past 2 days
- GI or GU bleeding within the past 14 days
- Endocarditis
- Severe hypertension (>200/120mmHg) at presentation
Vitamin K Antagonist
Blocks activation of vitamin K dependent prothrombotic factors II, VII, IX, X and blocks synthesis of vitamin K dependent ANTI-thrombotic proteins C and S
Heparins
Bind to and activate antithrombin, which in turns inactivates factor Xa and thrombin
Factor Xa Inhibitors
Inhibits Factor Xa, leading to inactivation of thrombin
- Rivaroxaban (Xarelto)
- Apixaban (Eliquis)
- Fondaparinux
- Edoxaban
Direct Thrombin Inhibitors
Self-explanatory
See Also
- Anticoagulant reversal for life-threatening bleeds
- Antiplatelet medications
- Procedures in patients with coagulopathies
References
- ↑ Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268–277.
